Abstract
Frequent use of high-quality cross-sectional imaging has led to a significant rise in diagnosis of pancreatic cystic lesions (PCLs). Despite the fact that enormous effort has been put into the research of PCLs within the last two decades and multiple guidelines have been developed, our clinical decision-making especially in regard to mucinous lesions remains limited. Currently, clinical assessment, cross-sectional imaging and EUS with fluid analysis (if appropriate) belong to the standard care in patients with PCLs. For differentiation of mucinous from nonmucinous cysts, the sensitivity of cytological investigation and CEA in the cyst fluid is 42% and 52-79%, respectively. Due to the limited accuracy, further diagnostic tools are warranted. Two EUS-guided approaches have been introduced recently. Through-the-(19-gauge EUS) needle Moray microforceps have been developed, and several studies have acknowledged their contribution to the correct diagnosis as they help to overcome limited cellularity of the EUS-guided cyst fluid aspiration and traditional cytology. Confocal laser endomicroscopy offers real-time images and seems to be a promising method for the diagnosis and differential diagnosis of pancreatic PCLs. Example images of the needle-based confocal laser endomicroscopy criteria for the diagnosis of PCLs have been suggested recently. Before both, Moray microforceps and confocal laser endomicroscopy can be widely accepted, further studies are necessary to determine the real diagnostic yield and the clinical efficacy.
Highlights
Frequent use of high-quality cross-sectional imaging has led to a significant rise in diagnosis of pancreatic cystic lesions (PCLs)
It has been acknowledged that individuals with PCLs have a significantly higher overall risk of pancreatic cancer [3]; clinicians face a challenge how to optimize management of individuals with a PCL, when currently insufficient diagnostic tools are taken into account [4]
Patients should not be overtreated with surgery and on the contrary, individuals with a malignant PCL should not be kept under surveillance inappropriately [5]
Summary
Frequent use of high-quality cross-sectional imaging has led to a significant rise in diagnosis of pancreatic cystic lesions (PCLs). The recent meta-analysis has confirmed pooled prevalence of 8% in asymptomatic individuals [1]. Incidence of PCLs increases with age and reaches 37% in patients aged >80 years [2]. It has been acknowledged that individuals with PCLs have a significantly higher overall risk of pancreatic cancer [3]; clinicians face a challenge how to optimize management of individuals with a PCL, when currently insufficient diagnostic tools are taken into account [4]. Patients should not be overtreated with surgery and on the contrary, individuals with a malignant PCL should not be kept under surveillance inappropriately [5]. The aim of our paper is to review classification of pancreatic cysts and to discuss the role of the most recent EUS- (endoscopic ultrasound-) guided diagnostic options for PCLs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
